Document is current
Any future updates will be listed below
-
Authors
De Luca, Roberto https://orcid.org/0000-0001-7519-8689
Neri, Dario https://orcid.org/0000-0001-5234-7370
-
Funding
Funding for this research was provided by:
European Research Council (Zauberkugel)
Swiss Federal Commission for Technology and Innovation (DUAL CYTOKINE-ANTIBODY FUSIONS)
- License Information
-
More Information
Article History
Received: 20 December 2017
Accepted: 29 June 2018
First Online: 4 July 2018
Compliance with ethical standards
:
: Dario Neri is co-founder, shareholder and member of the board of Philogen, a company working on antibody therapeutics. The authors declare no additional conflict of interest.
: Eight-week-old female BALB/c mice, 129/SvEv mice and C57BL/6 were obtained from Janvier Labs.
: Experiments were performed under a project license (license number 27/2015) granted by the Veterinäramt des Kantons Zürich, Switzerland, in compliance with the Swiss Animal Protection Act (TSchG) and the Swiss Animal Protection Ordinance (TSchV).
: Authentication of the cell lines also including check of post-freeze viability, growth properties and morphology, test for mycoplasma contamination, isoenzyme assay and sterility test was performed by the cell bank before shipment.
